Aviragen Therapeutics, Inc.

7.31+0.2500+3.54%Vol 497.63K1Y Perf -71.08%
Jun 29th, 2022 16:00 DELAYED
BID6.06 ASK7.40
Open7.01 Previous Close7.06
Pre-Market- After-Market-
 - -%  - -
Target Price
8.67 
Analyst Rating
Hold 2.83
Potential %
18.60 
Finscreener Ranking
★★★★★     60.26
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★★     70.39
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★★     69.73
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
4.81 
Earnings Rating
Strong Buy
Market Cap608.61M 
Earnings Date
11th Aug 2022
Alpha0.00 Standard Deviation0.33
Beta-0.72 

Today's Price Range

6.927.34

52W Range

5.3146.91

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-
1 Month
-
3 Months
3.25%
6 Months
-19.23%
1 Year
-71.08%
3 Years
-
5 Years
991.04%
10 Years
100.57%

TickerPriceChg.Chg.%
AVIR7.310.25003.54
AAPL139.231.79001.30
GOOG2 245.13-6.3000-0.28
MSFT260.263.78001.47
XOM88.12-3.3800-3.69
WFC39.71-0.4700-1.17
JNJ176.990.05000.03
FB196.640.99000.51
GE63.69-2.1900-3.32
JPM115.30-0.5200-0.45
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.58-0.5112.07
Q04 20210.331.34306.06
Q03 2021-0.05-0.34-580.00
Q02 20210.010.02100.00
Q01 2021-0.060.34666.67
Q03 2020-1.06-1.74-64.15
Q02 2018--0.09-
Q01 2018-0.14-0.140.00
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.4919.67Positive
9/2022 QR-0.5418.18Positive
12/2022 FY-2.2014.73Positive
12/2023 FY-1.4432.71Positive
Next Report Date11th Aug 2022
Estimated EPS Next Report-0.49
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume497.63K
Shares Outstanding83.26K
Shares Float63.21M
Trades Count5.05K
Dollar Volume3.60M
Avg. Volume316.36K
Avg. Weekly Volume168.98K
Avg. Monthly Volume310.98K
Avg. Quarterly Volume469.12K

Aviragen Therapeutics, Inc. (NASDAQ: AVIR) stock closed at 7.08 per share at the end of the most recent trading day (a 0.83% change compared to the prior day closing price) with a volume of 488.04K shares and market capitalization of 608.61M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drugs - Generic industry, Healthcare sector and employs people. Aviragen Therapeutics, Inc. CEO is .

The one-year performance of Aviragen Therapeutics, Inc. stock is -71.08%, while year-to-date (YTD) performance is -18.23%. AVIR stock has a five-year performance of 991.04%. Its 52-week range is between 5.31 and 46.9099, which gives AVIR stock a 52-week price range ratio of 4.81%

Aviragen Therapeutics, Inc. currently has a PE ratio of 14.60, a price-to-book (PB) ratio of 0.87, a price-to-sale (PS) ratio of 2.08, a price to cashflow ratio of 1.80, a PEG ratio of 2.32, a ROA of 6.21%, a ROC of 7.58% and a ROE of 7.65%. The company’s profit margin is 16.96%, its EBITDA margin is 23.00%, and its revenue ttm is $285.38 Million , which makes it $3.43 revenue per share.

Of the last four earnings reports from Aviragen Therapeutics, Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.49 for the next earnings report. Aviragen Therapeutics, Inc.’s next earnings report date is 11th Aug 2022.

The consensus rating of Wall Street analysts for Aviragen Therapeutics, Inc. is Hold (2.83), with a target price of $8.67, which is +18.60% compared to the current price. The earnings rating for Aviragen Therapeutics, Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aviragen Therapeutics, Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aviragen Therapeutics, Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 23.09, ATR14 : 0.38, CCI20 : 81.22, Chaikin Money Flow : 0.15, MACD : -0.22, Money Flow Index : 73.90, ROC : 28.73, RSI : 3.57, STOCH (14,3) : 80.19, STOCH RSI : 0.00, UO : 54.11, Williams %R : -19.81), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aviragen Therapeutics, Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (25.00 %)
1 (25.00 %)
1 (25.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (50.00 %)
2 (50.00 %)
2 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (25.00 %)
1 (25.00 %)
1 (25.00 %)
Summary RatingHold
2.83
Hold
2.83
Hold
2.83

CEO:

Telephone:

Address: , , ,

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

63%38%

Bearish Bullish

75%25%

Bearish Bullish

60%40%

News

Stocktwits